PortfoliosLab logoPortfoliosLab logo
THRY vs. MDGL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

THRY vs. MDGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Thryv Holdings, Inc. (THRY) and Madrigal Pharmaceuticals, Inc. (MDGL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, THRY achieves a -44.30% return, which is significantly lower than MDGL's -11.93% return.


THRY

1D
-3.71%
1M
-15.11%
YTD
-44.30%
6M
-43.55%
1Y
-73.17%
3Y*
-48.25%
5Y*
-37.25%
10Y*

MDGL

1D
1.41%
1M
-0.85%
YTD
-11.93%
6M
-14.92%
1Y
79.50%
3Y*
29.23%
5Y*
38.39%
10Y*
47.15%
*Multi-year figures are annualized to reflect compound growth (CAGR)

THRY vs. MDGL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
THRY
Thryv Holdings, Inc.
-44.30%-59.12%-27.27%7.11%-53.81%204.67%-3.57%
MDGL
Madrigal Pharmaceuticals, Inc.
-11.93%88.72%33.36%-20.28%242.52%-23.77%-6.37%

Correlation

The correlation between THRY and MDGL is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.02

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Oct 1, 2020

0.18

The correlation between THRY and MDGL shifts across timeframes, from 0.02 (1 year) to 0.20 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

THRY:

$152.48M

MDGL:

$14.89B

EPS

THRY:

$0.33

MDGL:

-$12.87

PS Ratio

THRY:

0.19

MDGL:

10.89

PB Ratio

THRY:

0.68

MDGL:

27.40

Total Revenue (TTM)

THRY:

$771.33M

MDGL:

$1.13B

Gross Profit (TTM)

THRY:

$522.68M

MDGL:

$1.05B

EBITDA (TTM)

THRY:

$81.86M

MDGL:

-$287.63M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

THRY vs. MDGL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

THRY
THRY Risk / Return Rank: 88
Overall Rank
THRY Sharpe Ratio Rank: 88
Sharpe Ratio Rank
THRY Sortino Ratio Rank: 88
Sortino Ratio Rank
THRY Omega Ratio Rank: 66
Omega Ratio Rank
THRY Calmar Ratio Rank: 88
Calmar Ratio Rank
THRY Martin Ratio Rank: 1111
Martin Ratio Rank

MDGL
MDGL Risk / Return Rank: 8383
Overall Rank
MDGL Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
MDGL Sortino Ratio Rank: 8585
Sortino Ratio Rank
MDGL Omega Ratio Rank: 8282
Omega Ratio Rank
MDGL Calmar Ratio Rank: 8282
Calmar Ratio Rank
MDGL Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

THRY vs. MDGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Thryv Holdings, Inc. (THRY) and Madrigal Pharmaceuticals, Inc. (MDGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


THRYMDGLDifference
Sharpe ratioReturn per unit of total volatility

-2.61

Sortino ratioReturn per unit of downside risk

-3.88

Omega ratioGain probability vs. loss probability

0.81

1.32

-0.51

Calmar ratioReturn relative to maximum drawdown

-0.86

2.72

-3.59

Martin ratioReturn relative to average drawdown

-1.32

5.88

-7.20

THRY vs. MDGL - Sharpe Ratio Comparison

The current THRY Sharpe Ratio is -0.87, which is lower than the MDGL Sharpe Ratio of 1.74. The chart below compares the historical Sharpe Ratios of THRY and MDGL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

THRY vs. MDGL - Drawdown Comparison

The maximum THRY drawdown since its inception was -94.96%, roughly equal to the maximum MDGL drawdown of -98.40%. Use the drawdown chart below to compare losses from any high point for THRY and MDGL.


Loading charts...

Drawdown Indicators


THRYMDGLDifference

Max Drawdown

Largest peak-to-trough decline

-94.96%

-98.40%

+3.44%

Max Drawdown (1Y)

Largest decline over 1 year

-84.84%

-29.36%

-55.48%

Max Drawdown (3Y)

Largest decline over 3 years

-91.69%

-49.34%

-42.35%

Max Drawdown (5Y)

Largest decline over 5 years

-94.96%

-61.41%

-33.55%

Max Drawdown (10Y)

Largest decline over 10 years

-82.19%

Current Drawdown

Current decline from peak

-91.92%

-14.92%

-77.00%

Average Drawdown

Average peak-to-trough decline

-47.69%

-58.48%

+10.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

55.42%

13.56%

+41.86%

Volatility

THRY vs. MDGL - Volatility Comparison

Thryv Holdings, Inc. (THRY) has a higher volatility of 19.49% compared to Madrigal Pharmaceuticals, Inc. (MDGL) at 13.40%. This indicates that THRY's price experiences larger fluctuations and is considered to be riskier than MDGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


THRYMDGLDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.49%

13.40%

+6.09%

Volatility (6M)

Calculated over the trailing 6-month period

81.34%

31.78%

+49.56%

Volatility (1Y)

Calculated over the trailing 1-year period

84.81%

46.00%

+38.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.55%

133.47%

-78.92%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

61.26%

117.50%

-56.24%

Dividends

THRY vs. MDGL - Dividend Comparison

Neither THRY nor MDGL has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

THRY vs. MDGL - Financials Comparison

This section allows you to compare key financial metrics between Thryv Holdings, Inc. and Madrigal Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
167.68M
311.34M
(THRY) Total Revenue
(MDGL) Total Revenue
Values in USD except per share items

THRY vs. MDGL - Profitability Comparison

The chart below illustrates the profitability comparison between Thryv Holdings, Inc. and Madrigal Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%20222023202420252026
65.2%
91.4%
Portfolio components
THRY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Thryv Holdings, Inc. reported a gross profit of 109.26M and revenue of 167.68M. Therefore, the gross margin over that period was 65.2%.

MDGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a gross profit of 284.49M and revenue of 311.34M. Therefore, the gross margin over that period was 91.4%.

THRY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Thryv Holdings, Inc. reported an operating income of 4.06M and revenue of 167.68M, resulting in an operating margin of 2.4%.

MDGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported an operating income of -92.72M and revenue of 311.34M, resulting in an operating margin of -29.8%.

THRY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Thryv Holdings, Inc. reported a net income of 4.54M and revenue of 167.68M, resulting in a net margin of 2.7%.

MDGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a net income of -94.39M and revenue of 311.34M, resulting in a net margin of -30.3%.


Frequently Asked Questions


THRY and MDGL have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

THRY has higher volatility (19.49%) compared to MDGL (13.40%). In terms of maximum drawdown, THRY dropped -94.96% vs MDGL's -98.40%.

MDGL currently has the higher Sharpe Ratio (1.74 vs -0.87), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for THRY and MDGL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer